Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Oncogene|June 16, 2015
Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cellsI V Fedorenko, E V Abel, J M Koomen, et al.
Nature|February 5, 1998
Geological evidence for solid-state convection in Europa's ice shellR T Pappalardo, J W Head, R Greeley, et al.
Neurology|March 1, 1992
Quantitative cerebral anatomy of the aging human brain: a cross-sectional study using magnetic resonance imagingC E Coffey, W E Wilkinson, I A Parashos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol QK L Jhaveri, X V Wang, V Makker, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 26, 1999
Spinal-flexibility-plus-aerobic versus aerobic-only training: effect of a randomized clinical trial on function in at-risk older adultsM C Morey, M Schenkman, S A Studenski, et al.
Investigational New Drugs|January 3, 2021
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancersJ Wu, D Liu, M Offin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyG V Long, K T Flaherty, D Stroyakovskiy, et al.
NPJ Precision Oncology|March 2, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trialA S Mansfield, Z Wei, R Mehra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2016
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabA M Menzies, D B Johnson, S Ramanujam, et al.
Science (New York, N.Y.)|December 4, 2004
Localization and physical property experiments conducted by Opportunity at Meridiani PlanumR E Arvidson, R C Anderson, P Bartlett, et al.
Pageof 9